Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high
energy x-rays to kill cancer cells. Giving chemotherapy together with radiation therapy may
kill more cancer cells. Diagnostic procedures, such as PET scan, done before, during, and
after chemotherapy may help doctors plan the best treatment.
PURPOSE: This phase II clinical trial is studying how well response-based therapy assessed
by PET scan works in treating patients with bulky stage I and stage II Hodgkin lymphoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.